Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohammad Wafa

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Frontiers in Psychology|June 15, 2026
Hemispheric disparity theory: a dual-system framework for consciousnessMohammad Wafa
Multiple Sclerosis and Related Disorders|January 24, 2026
Lost in space, lost in time: A clinician's proposed approach to the diagnosis of multiple sclerosisMohammad Wafa, Gavin Giovannoni
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 22, 2023
A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosisRuth Dobson, David Holden, Nicola Vickaryous, et al.
Multiple Sclerosis and Related Disorders|December 25, 2025
The brainstem signature of multiple sclerosis: predictable lesions, consistent syndromesMohammad Wafa, Khalid Nuh, Gavin Giovannoni, et al.
Clinical Immunology (Orlando, Fla.)|October 20, 2024
Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cellsFrancesca Ammoscato, Mohammad Wafa, Justyna Skonieczna, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Frontiers in Psychology|June 15, 2026
Hemispheric disparity theory: a dual-system framework for consciousnessMohammad Wafa
Multiple Sclerosis and Related Disorders|January 24, 2026
Lost in space, lost in time: A clinician's proposed approach to the diagnosis of multiple sclerosisMohammad Wafa, Gavin Giovannoni
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 22, 2023
A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosisRuth Dobson, David Holden, Nicola Vickaryous, et al.
Multiple Sclerosis and Related Disorders|December 25, 2025
The brainstem signature of multiple sclerosis: predictable lesions, consistent syndromesMohammad Wafa, Khalid Nuh, Gavin Giovannoni, et al.
Clinical Immunology (Orlando, Fla.)|October 20, 2024
Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cellsFrancesca Ammoscato, Mohammad Wafa, Justyna Skonieczna, et al.
Pageof 1